• Home
  • Motorcycles
  • Electric Motorcycles
  • 3 wheelers
  • FUV Electric 3 wheeler
  • Shop
  • Listings

Subscribe to Updates

Get the latest creative news from CycleNews about two, three wheelers and Electric vehicles.

What's Hot

2025 Thunder Valley National Motocross Fantasy Picks: Fast Facts

2025 BMW R 1300 GS Adventure to Quail MotoFest: A Travel Story

Silicon Valley Is Starting to Pick Sides in Musk and Trump’s Breakup

Facebook Twitter Instagram
  • Home
  • Motorcycles
  • Electric Motorcycles
  • 3 wheelers
  • FUV Electric 3 wheeler
  • Shop
  • Listings
Facebook Twitter Instagram Pinterest
Cycle News
Submit Your Ad
Cycle News
You are at:Home » The Race for the Next Ozempic
Electric Motorcycles

The Race for the Next Ozempic

cycleBy cycleJuly 24, 202403 Mins Read
Share Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email


In the 1980s, researchers identified a hormone in the human gut called GLP-1 that triggers the release of insulin, which controls blood sugar levels. The discovery would eventually launch a new class of diabetes drugs known as GLP-1 receptor agonists, the first of which was approved in 2005.

The drugs not only kept blood sugar in check. Curiously, they also seemed to suppress appetite, and some people taking them lost a modest amount of weight. The revelation led the US Food and Drug Administration to approve the first GLP-1 drug for weight loss in 2014. Called liraglutide and sold under the brand name Saxenda, the weekly injectable led to a nearly 3 percent reduction in body weight on average in trial participants who took it.

By then, Novo Nordisk, the maker of Saxenda, was already working on a better GLP-1. This new drug, semaglutide, was first approved for diabetes in 2017 under the brand name Ozempic and then in 2021 for weight loss as Wegovy. In trials of the drug, participants who received Wegovy lost around 15 percent of their initial body weight—a total game changer.

Hot on the heels of semaglutide is Eli Lilly’s tirzepatide, approved as Mounjaro in 2022 for diabetes and as Zepbound in 2023 for weight management. In studies of Zepbound, patients taking the highest dose lost around 21 percent of their body weight. In a head-to-head comparison of Wegovy and Zepbound published earlier this month, Zepbound was found more likely to lead to significant weight loss.

These drugs are now wildly popular, in shortage as a result, and hugely profitable for the companies making them. Their success has sparked a frenzy among pharmaceutical companies looking for the next blockbuster weight-loss drug. Researchers are now racing to develop new anti-obesity medications that are more effective, more convenient, or produce fewer side effects than the ones currently on the market. The existing drugs can cause nausea, headaches, and other unpleasant side effects that lead some people to stop taking them.

They have other downsides too. In the United States, they can cost more than $1,000 a month and aren’t always covered by insurance. They have to be injected under the skin once a week. And while most people who stay on them see positive results, others don’t lose much weight at all. Not to mention ongoing shortages of GLP-1s are making it hard for patients to start and continue taking them as prescribed.

Having more drugs on the market would mean more choices for patients—and more profits for the companies selling them. “It’s an extraordinarily exciting and busy time in the field of obesity,” says Darren McGuire, a cardiologist and professor of internal medicine at University of Texas Southwestern Medical Center.

Semaglutide and tirzepatide work by activating GLP-1 receptors in the pancreas to stimulate the production of insulin, which helps to control blood sugar levels in people with type 2 diabetes. These drugs also slow down the emptying of the stomach and interact with GLP-1 receptors in the brain to tamp down hunger. As a result, people tend to eat less and have fewer food cravings while taking them.

It’s possible that tirzepatide is slightly more effective because it’s a dual receptor agonist. In addition to GLP-1, it also activates receptors of GIP, another hormone involved in regulating blood sugar and appetite. But McGuire says GIP isn’t well understood, and it’s not clear whether the addition of GIP is driving the increased weight loss or if tirzepatide is just better at activating GLP-1. “We just don’t have a way to unravel that biology right now,” he says.



Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Previous ArticleArcimoto unveils updated radical 3-wheeled e-bike known as the Mean Lean Machine (MLM) – Electrek.co
Next Article This 50 MPH fully-enclosed electric vehicle offers car-like convenience in a motorcycle size – Electrek.co
cycle
  • Website

Related Posts

Silicon Valley Is Starting to Pick Sides in Musk and Trump’s Breakup

June 5, 2025

Elon Musk’s Feud With President Trump Wipes $152 Billion Off Tesla’s Market Cap

June 5, 2025

Elon Musk Is Posting Through It

June 5, 2025
Add A Comment

Leave A Reply Cancel Reply

You must be logged in to post a comment.

Demo
Top Posts

2025 Thunder Valley National Motocross Fantasy Picks: Fast Facts

June 6, 2025

The urban electric commuter FUELL Fllow designed by Erik Buell is now opening orders | thepack.news | THE PACK

July 29, 2023

2024 Yamaha Ténéré 700 First Look [6 Fast Facts For ADV Riding]

July 29, 2023
Stay In Touch
  • Facebook
  • YouTube
  • TikTok
  • WhatsApp
  • Twitter
  • Instagram
Latest Reviews

Subscribe to Updates

Get the latest tech news from FooBar about tech, design and biz.

Demo
Most Popular

2025 Thunder Valley National Motocross Fantasy Picks: Fast Facts

June 6, 2025

The urban electric commuter FUELL Fllow designed by Erik Buell is now opening orders | thepack.news | THE PACK

July 29, 2023

2024 Yamaha Ténéré 700 First Look [6 Fast Facts For ADV Riding]

July 29, 2023
Our Picks

The Plan to Put Pig Genes in Soy Beans for Tastier Fake Meat

7 Best E-Readers (2024): Kindle, Nook, Kobo

35 Best Black Friday Mattress Deals (2023): Foam, Hybrid, and Sheets

Subscribe to Updates

Get the latest news from CycleNews about two, three wheelers and Electric vehicles.

© 2025 cyclenews.blog
  • Home
  • About us
  • Get In Touch
  • Shop
  • Listings
  • My Account
  • Submit Your Ad
  • Terms & Conditions
  • Stock Ticker

Type above and press Enter to search. Press Esc to cancel.